Cancers with a higher number of mutations are more likely to be susceptible to immunotherapy.

“the more mutations a cancer has the more likelihood that it will produce an antigen that's recognized as non-self and that's why in the early days of immunotherapy the only things that worked were I to against metastatic melanoma and kidney cancer because kidney cancer turned out to also be one of those cancers that for reasons that are not clear produced hundreds of mutations”